VALANX Biotech
PrivateLast Round
Series A
Mar 12, 2026
Total Funding Raised
$3.55M
Company Overview
VALANX Biotech operates in Healthcare & Life Sciences and is based in Klosterneuburg. Its latest recorded funding round was a Series A round in March 2026.
VALANX Biotech is a biotechnology company that has developed a proprietary platform for site-specific protein conjugation to create antibody-drug conjugates (ADCs) and other biologics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VALANX Biotech Comparables
Compare VALANX Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BrickBio, Inc. | 87% | |
| Catena Biosciences | 84% | |
| Onegene Biotechnology | 79% |
For institutional investors. Book with your work email.
VALANX Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 12, 2026 | ||||
| VC Round | Nov 7, 2023 | ||||
| Seed | May 1, 2020 | ||||
| Accelerator | Jun 16, 2017 |
For institutional investors. Book with your work email.
VALANX Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| tecnet equity | Seed, Series A, VC Round |
| Skygene | Series A, VC Round |
| xista science ventures | Seed, VC Round |
| xista science ventures | Series A |
| RebelBio | Accelerator |
| SOSV | Seed, Series A, VC Round, Accelerator |
| Fondation Fournier-Majoie | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 2, 2026
Grew 21% QoQ, from 14 to 17 employees.
- Apr 15, 2026
Monthly visitors increased 144% MoM, reaching 268.
For institutional investors. Book with your work email.
VALANX Biotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about VALANX Biotech's valuation, stock price, and market status.
Is VALANX Biotech a public or private company?
VALANX Biotech is a private company.
What is the current stock price of VALANX Biotech?
VALANX Biotech is a private company, so its shares have no public market price. Caplight tracks VALANX Biotech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is VALANX Biotech worth (valuation)?
Valuation information for VALANX Biotech is not publicly available.
Can I buy VALANX Biotech stock?
VALANX Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was VALANX Biotech's last funding round?
VALANX Biotech's most recent funding round was Series A on March 12, 2026.
Who are the main investors in VALANX Biotech?
Key investors in VALANX Biotech include Skygene, RebelBio, Fondation Fournier-Majoie, Fujifilm Corporation.
Will VALANX Biotech IPO soon?
No public IPO plans have been announced for VALANX Biotech.
How can I track VALANX Biotech secondary market activity?
Caplight tracks bids, offers, and trades in VALANX Biotech's shares on secondary markets.